Site Map


Home

EFFICACY

Non-Small Cell Lung Cancer (NSCLC)
Metastatic/Recurrent or Early-Stage

Renal Cell Carcinoma (RCC)
Advanced

Gastroesophageal Cancers
Metastatic and Adjuvant

Melanoma
Adjuvant Therapy and Advanced Disease

Urothelial Carcinoma (UC)
Locally Advanced or Metastatic and Adjuvant Therapy

MSI-H/dMMR Colorectal Cancer (CRC)
1L Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

Hepatocellular Carcinoma (HCC)
1L Treatment of Unresectable or Metastatic Hepatocellular Carcinoma

Subcutaneous Treatment Option

Dual I-O Treatment Option

Indications in Earlier Stages of Cancer

SAFETY

Non-Small Cell Lung Cancer (NSCLC)
Metastatic/Recurrent or Early-Stage

Renal Cell Carcinoma (RCC)
Advanced

Gastroesophageal Cancers
Metastatic and Adjuvant

Melanoma
Adjuvant Therapy and Advanced Disease

Urothelial Carcinoma (UC)
Locally Advanced or Metastatic and Adjuvant Therapy

MSI-H/dMMR Colorectal Cancer (CRC)
1L Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

Hepatocellular Carcinoma (HCC)
1L Treatment of Unresectable or Metastatic Hepatocellular Carcinoma

DOSING SCHEDULES

Non-Small Cell Lung Cancer (NSCLC)
Metastatic/Recurrent or Early-Stage

Renal Cell Carcinoma (RCC)
Advanced

Gastroesophageal Cancers
Metastatic and Adjuvant

Melanoma
Adjuvant Therapy and Advanced Disease

Urothelial Carcinoma (UC)
Locally Advanced or Metastatic and Adjuvant Therapy

MSI-H/dMMR Colorectal Cancer (CRC)
1L Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

Hepatocellular Carcinoma (HCC)
1L Treatment of Unresectable or Metastatic Hepatocellular Carcinoma

Other Tumor Types

All Indications